New England journal report describes unique features of adverse reactions in TGN1412 trialBMJ 2006; 333 doi: https://doi.org/10.1136/bmj.333.7568.570-a (Published 14 September 2006) Cite this as: BMJ 2006;333:570
- Susan Mayor
The healthy volunteers who took part in the clinical trial of the anti-CD28 monoclonal antibody TGN1412 had multiple organ failure similar to that seen in septic shock but with several unique features, says a report published last week by Dr Suntharalingam and his colleagues, who cared for the six men after they were transferred to the NHS (New England Journal of Medicine 2006;355:1018-28).
Within 90 minutes of receiving a single intravenous dose of TGN1412 all six volunteers had a systemic inflammatory response characterised by a rapid …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial